Summary
A newborn boy with family history of severe ornithine transcarbamylase (OTC) deficiency was investigated prospectively and managed aggressively at birth based on an existing protocol for at risk neonates. Undetectable citrulline levels at birth suggested that the infant was affected; however, normal plasma glutamine and urine orotic acid levels confused the diagnosis to some extent. Mutation testing confirmed that the patient did not have OTC deficiency. Thus the low plasma citrulline level did not validate our initial biochemical suspicion of OTC deficiency, and this highlights the importance of considering all available clinical, biochemical and molecular evidence in determining disease status.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicating editor: Christine Vianey-Saban
Online citation: JIMD Short Report #045 (2007) Online
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Chiong, M.A., Carpenter, K. & Christodoulou, J. Low citrulline may not be diagnostic of ornithine transcarbamylase deficiency: A case report. J Inherit Metab Dis 30, 405 (2007). https://doi.org/10.1007/s10545-007-0495-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-007-0495-0